A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and with Combination Therapies in Patients With Solid Tumors

This is a First In Human (FIH) study Phase 1a - Dose Escalation and Phase 1b - Dose Expansion to investigate the safety, tolerability, pharmacokinetics, and preliminary antitumour activity of Second Mitochondria-derived Activator of Caspases (Smac) Mimetic BGB-24714 as monotherapy and in combination with chemotherapy in participants with advanced solid tumours. Eligible participants will be limited to those with solid tumours who have not been treated with Smac mimetics previously. For BGB-24714 monotherapy will recruit participants with advanced solid tumours who have previously received systemic therapy or for whom treatment is not available, not tolerated, or refused. For BGB-24714 in combination with chemotherapy, will recruit participants with advanced solid tumours for whom paclitaxel monotherapy is appropriate per the investigator's discretion. The following indications include but are not limited to platinum resistant ovarian, triple-negative breast cancers, oesophageal squamous cell carcinoma, head and neck squamous cell cancer, nasopharyngeal carcinoma, non-small cell lung cancer, gastric and cervical cancers. Tumour types not listed above may be considered after sponsor consultation. There will be 4 sites in Australia.